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Summary
The multifunctional cytokine, transforming growth factor beta (TGF-a), was identified by
immunocytochemistry in the brain tissues of four patients with acquired immune deficiency
syndrome (AIDS), but not in control brain tissue. The TGFO staining was localized to cells
of monocytic lineage as well as astrocytes, especially in areas of brain pathology. In addition,
the brain tissues from the AIDS patients contained transcripts for human immunodeficiency virus
1 (HIV1) by in situ hybridization, suggesting a correlation between the presence of HIV-1 in
the brain and the expression of TGF-0. However, the expression of TGFO was not limited to
HIV-1-positive cells, raising the possibility of alternative mechanisms for the induction of TGFO
in these AIDS patients' brains. To investigate these mechanisms, purified human monocytes were
infected in vitro with HIV-1 and were shown to secrete increased levels of TGF-(3. In addition,
HIV-1-infected monocytes released a factor(s) capable of triggering cultured astrocytes that are
not infected with HIV-1 to secrete TGF-/3. The release of TGF-0, which is an extremely potent
chemotactic factor, may contribute to the recruitment ofHIV-1-infected monocytic cells, enabling
viral spread to and within the central nervous system (CNS). Moreover, TGFO augments cytokine
production, including cytokines known to be neurotoxic. The identification of TGFO within
the CNS implicates this cytokine in the immunopathologic processes responsible for AIDS-related
CNS dysfunction.
entral nervous system (CNS)t dysfunction is a common
manifestation of AIDS. CNS dysfunction of the brain
in patients with AIDS may result from primary infection with
HIV-1 (1-7), opportunistic infections (8-10), and/or neoplasms
(10, 11). However, the most common syndrome in AIDS-
related CNS disease is HIV encephalopathy, a fatal dementing
illness that may occur in the absence ofopportunistic pathogens
or neoplasms. Although the cellular and molecular events
leading to HIV encephalopathy are unclear, a consistentfinding
in the brains of AIDS patients is infiltration by monocyte-
macrophages, cells that appear to be the predominant source
of HIV-1 within the brain (1, 2, 12). Since monocytes play
a critical role in the pathogenesis of HIV-1 infection and in
the evolution of AIDS (13-19), this population of cells may
1 Abbreviations used in this paper . CNS, central nervous system; DTT,
dithiothreitol; GFAP, glial fibrillary acidic protein; RT, reverse transcriptase.
contribute to the neuropathology associated with AIDS-related
CNS dysfunction. Consistent with this hypothesis are the
recent observations that peripheral blood monocytes infected
with HIV-1 constitutively release cytokines such as TNF-ci
(20, 21), which is reportedly neurotoxic (22, 23) and may
contribute to the brain pathology. In addition, the accumu-
lation of monocyte-macrophages in the CNS suggests the
presence of a mechanism for recruitment of circulating mono-
cytes into these tissues.
Recently identified as a cytokine with potent chemotactic
activity for monocytes, TGF-a can induce migration at fem-
tomolar concentrations (24). To determine whether TGFO
plays a role in recruitment and regulation ofmonocyte func-
tion in the CNS in AIDS patients, we evaluated brain tissue
obtained at autopsy or surgery from AIDS patients for the
presence of this immunoregulatory cytokine. TGF-(3 was
clearly identified within the AIDS brain tissues in associa-
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981-991tion with the mononuclear phagocytic cells and also cells
identified as astrocytes. To determine whether HIV-1 could
regulate the production of this polypeptide, we infected pe-
ripheral bloodmonocytes with HIV-1 in vitro andmonitored
theirsecretion of TGF-/3. Theinfected monocyticcells secreted
TGF-0 and released a factor(s) that triggered secretion of
TGF-0 by cultured, uninfected astrocytes. Identification
of TGF-R, a cytokine with numerous immunoregulatory func-
tions (25), in theHIV-1-infected braintissues suggests arole
for this cytokine in the pathobiology of HIV encephalopathy.
Materials and Methods
Patients and Tissue Specimens.
￿
Tissue specimens were obtained
at autopsy (patients 1-3) and surgery (patient 4) from the brains
of four male subjects with AIDS (Table 1). The brains were posi-
tive forHIV as determined by electron microscopic evaluation (26)
and/or in situ hybridization; in some casesopportunistic pathogens
could be detected. The histopathology of two of the AIDS pa-
tients (patients 1 and2) has been describedin detail previously (26).
Controlbraintissue wasobtained at autopsyfrom aperson without
AIDS or other CNSdefects (patient 5) andfrom abiopsy of a pa-
tient with meningioma (patient 6).
Histology andImmunohistochemistry.
￿
Brain tissue specimenswere
fixed in 10% buffered formalin, embedded in paraffin, sectioned,
and stained with hematoxylin andeosinfor neuropathologic evalu-
ation. Immunohistochemical staining was performed using the
horseradish-peroxidase-labeled avidin-biotin procedure (ABC Vecta
Stain Kit; Vector Laboratories Inc., Burlingame, CA) with di-
aminobenzidine as chromogen (27). Antibodies included onepre-
pared against a synthetic polypeptide identical to the NHa ter-
minalresidues 1-30 of TGF-01(28), amAbdirected at glialfibrillary
acidic protein (GFAP; Dakopatts, Carpenteria, CA) that is specific
forastrocytes (29), LeuM1, Leu1,andFILE,whichrecognizemono-
cytes, lymphocytes, and human leukocyte antigens, respectively
(Becton Dickinson and Co., Mountain View, CA). After im-
munoperoxidase staining, theslides were counterstained withmethyl
green. Additional sections were processed for visualization of the
enzyme a-napthyl-acetate-esterase (30) andwith amodified Scott's
stain for oligodendroglia, microglia, and astrocytes.
In Situ Hybridization.
￿
Tissue sections (6-8 Am)were fixedwith
periodate-lysine-paraformaldehyde-glutaraldehyde onto silanized
slides as described (1, 31). Afterdeparaffinization ofthetissue sec-
tionswith xylene, thesections were permeabilizedwith proteinase
K(100 Ag/ml), acetylated, dehydrated, andprehybridized. Thetissue
sections were hybridized to a [31S]-labeled RNA probe encoding
pooled portions of the HIV-1 gag/pol/env regions in sense or an-
tisense orientation (106 cpm/slide) (Lofstrand, Gaithersburg, MD)
in thepresence of 1x Denhardt's solution with 10 mM dithiothre-
itol (DTT), 0.3 MNaCl, 50 mM Tris-HCI, and 10% dextran sul-
fate in formamideovernightat 48°C (31). Theslides were washed
sequentially in 2x SSC (1x SSC - 0.15 M NaCl/0.015 M Na
citrate, pH 7.0), 2x SSC with 1 mM EDTA, 5 mM DTT, and
0.1% Triton X-100 at 56°C, and 0.1x SSC with EDTA, DTT,
and Triton X-100. The slides then were treated with ribonuclease
A (40 Ag/ml) and T (10 U/ml) (Sigma Chemical Co., St. Louis,
MO) in 2x SSC at 37°C for 40 min, washed in 2x SSC, and
dehydrated in graded ethanols. Slides were prepared for autoradi-
ography with NTB3 emulsion (Eastman Kodak, Co., Rochester,
NY), developedafter 3dand stainedwith hematoxylin andeosin.
Cultured cells were processed and were hybridized to a [3'S]-la-
beled cDNATGF-S1 antisense probe (32) as described above and
the autoradiography developed after 21 d.
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Mononuclear LeukocyteSuspensions.
￿
Mononuclear leukocytes were
isolated from heparinized peripheral blood of healthy volunteers
or from leukapheresis units (National Institutes of Health Blood
Bank,Bethesda, MD)by Ficoll-Paque densitygradient centrifuga-
tion (33).To obtain highly purified populations of monocytes, the
mononuclear leukocytes were separatedby counterflow centrifugal
elutriation in pyrogen-free PBS (B &B/Scott, Fiskville, RI) as de-
scribed (33).
In Vitro Infection with HIV-1.
￿
Purified monocytes (10') were
cocultured with macrophage tropic HIV1H.L (5 x 105 cpm reverse
transcriptase [RT] activity, kindly providedby Drs. S. Gartnerand
M. Popovic, National Cancer Institute, Bethesda, MD) in suspen-
sion or in adherent monolayers as described (14, 16). Monocytes
were suspendedin RPMI 1640 (Gibco Laboratories, Grand Island,
NY)with 50 Ag/ml gentamicin, 2 mM glutamine, and 20% FCS
with or withoutvirus for 1 hwith intermittent shaking at 37°C.
The cells were then washed and resuspended (2 x 106/ml) in
medium containing 10% FCS for suspension cultures in 17 x
100-mm polypropylene tubes (Falcon Labware, Oxnard, CA) or
resuspended in medium without serum forplating (106/ml) in 24-
well tissue culture plates (Falcon Labware). After 2-4 h, the ad-
herent cells were washed, and medium containing 10% FCS was
added.Media(50%) were removedandfreshmedium addedat 3-4-d
intervals.
Alternatively, monocytes were cultured as adherent monolayers
for 5-7 dand then incubated with HIV-1 for 1-2 h, washed, and
fresh serum-supplemented medium wasadded.Infectionwas moni-
tored by RT assay, HIV p24 antigen capture ELISA (NEN Re-
search Products, Boston, MA), and/or by electron microscopy (16).
TCR0 Assay.
￿
TGF-S in culture supernatants wasquantitated
by itsability to inhibitthymocyteproliferation (34). SinceTGF-0
is normally secreted in a latent form, the supernatants were either
acid activated (1.5 A1 6 N HCI/200 pl supernatant) for 15 min,
followed by neutralization with 6NNaOH in 1 MHepesor heated
to 80°C for5 min(34). The treated supernatants then were added
in twofold dilutions to cultures of C3H/HeJ mouse thymocyyes
containing 10 U/ml ILA andPHA(1 Fcg/ml) in parallel with serial
dilutions ofaTGF-0standard (R&DSystems, Minneapolis, MN).
After 68 h, the wells were pulsed for 4 h with 0.5 p.Ci/ml
['H]TdR(Schwarz-Mann, Orangeburg, NY) (sp act 1.9 Ci/mM),
harvested, and processed for determination of ['H]TdR incorpo-
ration. In this assay, the inhibitory concentration (ICso) is -0.05
ng TGF-Q/ml and this activity canbe blocked with a neutralizing
antibody to TGF-0 (34).
Northern Blot Analysis.
￿
Total RNA was isolated from 1.5 x
10' control monocytes or monocytes exposed to HIV-1 for 1 h,
washed, and cultured forup to 21 d. Total RNA wasprepared by
the acid guanidinium thiocyanate-phenol-chloroform extraction pro-
cedure (35). For Northern blots, 5 Ag RNA was fractionated on
1.0% agarose gels containing formaldehyde and transferred to
nitrocellulose filters. Theblotswere prehybridized and then sequen-
tially hybridized with the "P-labeled cDNA probes: HIV-1 (a 6.5-
kb segment of HIV-1 encoding gag/pol/env), human TGF-01
(provided by Dr. R. Derynck, Genentech Inc., South San Fran-
cisco, CA) (32), and He7 (provided by Dr.J. Reed, University of
Pennsylvania School of Medicine, Philadelphia, PA)(36). Theblots
were washed twicein 2x SSC, 0.1% SDS for15 min at room tem-
perature and for 30 min at 65°C in 0.1x SSC, 0.1% SDS. The
filters were exposed to Kodak XAR film with intensifier screens
at -70°C for 4-18 h. The relative amounts of hybridizing RNA
were determined by scanning the autoradiograms with alaserden-
sitometer (LKB Ultrascan, LKB Instruments, Gaithersburg, MD)
and the TGF-S/He7 ratios determined for individual samples.
Astrocyte Isolation and Culture.
￿
Primary glial cell cultures were
in AIDSestablished from neonatal rat brain hemispheres as previously de-
scribed (37). Briefly, after removal of meninges, the brain tissue
was trypsinized (0.5 mg/ml) in HBSS without Cal" and Mgx.
for 15 min at room temperature. Serum-containing DMEM was
added to stop trypsinization, and the cells were mechanically dis-
sociated in 0.5 /ug/ml DNase I (Sigma Chemical Co.), washed,
and suspended in DMEM with antibiotics, glutamine, and 10%
FCS. The cells were plated in 75-cmz tissue culture flasks (Nunc)
coated with 0.1 mg/ml poly-L-lysine (Sigma Chemical Co.), and
cultured at 37°C for 8-10 d. The adherent astrocytes were tryp-
sinized and replated in poly-L-lysine-coated culture dishes. After
a second trypsinization, astrocytes were plated at 7.5 x 10'/well
in 24-well tissuecultureplates and the cells grown to nearconfluency.
The medium was aspirated and replaced with DMEM with 10%
FCS containing dilutions of supernatants obtained from HIV-1-
infected or control monocyte cultures. Additionally, 1-20 ng/ml
TGF-O was added to astrocyte cultures. After a 4-5-h incubation,
medium was removed and discarded, the cells were washed exten-
sively, and fresh DMEM was added for 36 h. At the end of this
incubation, the cell-free astrocyte supernatants were harvested and
frozen until assayed for TGF-0.
Results
Identification ofTGRO in Brains ofPatients with AIDS.
￿
The
histological alterations of the brain tissues are summarized
in Table 1. Compared to normal brain tissue, the brains of
the four AIDS patients had varying degrees of cellular
infiltrates, primarily mononuclear in composition, as well as
areas oftissue damage, multinucleated giant cells, phagocytes
with foamy cytoplasm, and gliosis. By immunoperoxidase
staining with an antibody that detects primarily intracellular
TGF-01(27), many cells in each of the AIDS patients' brain
stained prominently for TGF-01 (Fig. 1 B and Table 1).
Specificity of the antibody for TGF-0 was documented by
the absence of staining after this IgG preparation had been
incubated with Sepharose-coupled TGF-01 (kind gift of Dr.
K. Flanders, National Cancer Institute) as described (38). The
presence ofTGF-01 in the AIDS patients' brains was in marked
contrast to its absence in the brain tissue sections from the
subject without CNS pathology (patient 5, Fig. 1 E). Sec-
PML, progressive multifocal leukoencephalopathy.
t PV, papovavirus; CMV, cytomegalovirus; toxo, toxoplasma.
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tions of the meningioma from patient 6 were negative for
TGF-01, although a number ofcells that had infiltrated around
the tumor mass stained positively for TGF-01 (Table 1).
The TGF-01 in the AIDS patients' brains appeared to
localize preferentially within the white matter. Staining often
occurred near the ependyma and frequently exhibited a gra-
dient pattern (Fig. 2 E) in which cells adjacent to the site
of pathology stained intensely for TGF-0 compared to the
progressive reduction in intensity and number ofpositive cells
in areas more distant from these foci.
Characterization ofCellsExpressing TGRO.
￿
Closer exami-
nation of the TGF-# positive brain sections from the AIDS
patients allowed for identification of the cellular loci of
the TGF-O polypeptide. Many cells with morphologic char-
acteristics of cells in the mononuclear phagocytic lineage
were located in perivascular locations and stained positively
for TGF-0 (Fig. 2 A). Among these positively staining cells
were multinucleated giant cells (Fig. 2 B) and mononuclear
phagocytes some of which appeared to contain TGF-0within
phagocytic vacuoles (Fig. 2 C). In addition, a population of
cells with the distribution, morphology, and GFAP staining
characteristics of astrocytes were positive for TGF-01 (Fig.
2 E and F). Moreover, many of these astrocytes appeared ac-
tivated as reflected by their enlarged nuclei and cytoplasmic
profiles. TGF-01 staining did not appear in oligodendrocytic,
neuronal, or endothelial cell populations. Interestingly, the
astrocyte and macrophage populations in the AIDS brains
were not universally positive for TGF-0, but positive cells
were localized in and around areasofapparent tissue pathology.
Localization ofHIV1.
￿
Since mononuclear phagocytes in-
fected with HIV-1 in vitro and in vivo may express increased
levels ofcertain cytokines (20, 21), we next evaluated whether
the cells expressing TGF-0 also were infected with HIV.1.
Sequential brain sections were either probed by,in situ hy-
bridization with the ['SS]-labeled antisense RNA probe for
pooled HIV-1 gag/pol/env regions or stained by the im-
munoperoxidase procedure for TGF-01. Grains representing
copies of HIV-1-specific RNA were present over multinu-
cleated giant cells and other cells that appeared to be ofmono-
cytic lineage, but not over cells identified as astrocytes (Fig.
us agent#
CMV TOXO
Table 1 . Pathology
Patient
and Identification
TGF-0
of TGF,B in Brain Tissue of AIDS Patients and Control Subjects
Infecti
Pathology HIV-1 PV
1 (Autopsy) + + PML"
2 (Autopsy) + + Lymphoma
3 (Autopsy) + + Lymphoma
4 (Biopsy) + + Toxoplasmosis
5 (Autopsy) - Normal
6 (Biopsy) ± MeningiomaFigure 1 .
￿
Identification ofTGF-(3 by immunocytochemistry. Formalin fixed brain tissue from an AIDS patient (A-C) and a patient without brain
pathology (D and E) were stained with H& E (A and D) or by immunoperoxidase with an antibody prepared against a synthetic polypeptide identical
to the NHZ-terminal residues 1-30 of TGF-S (B and E) . (C) Patient tissue treated as in B without primary antibody (original magnification, x32) .
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Localization ofTGF-O peptide and HIV -1 RNA in AIDS brain tissues . Immunocytochemical staining for TGF-O in (A) perivascular regions
(original magnification, x32) ; (B) multinucleated giant cells (original magnification, x 250) and (C) vacuolated phagocytic cells (original magnification,
x 250) . (D) In situ hybridization for HIV-1mRNA . Sections ofbrain tissue from patient 3 stained with TGFLO (E) and GFAP (F) (original magnification,
x32) .
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Production of TGF-ß by HIVinfected Mnocytes . Purified
monocytes were exposed to HIV1B,_y (5 x 105 cpm/106 monocytes) for
1 h, washed, and adhered in tissue culture wells. DMEM containing 10%
FCS was added and at indicated intervals, 50% of the medium was re-
moved and replaced with freshDMEM and FCS. TGF-0 activity in the
harvested supernatants was determinedasdescribed in MaterialsandMethods
and is representative of three experiments.
2D) . Sections from the same brains using control sense probes
were negative . There did not, however, appear to be a direct
concordance between the presence ofHIV-1 and TGF-ß, in
that many more cells were TGF-ß positive than were HIV-1
positive . Moreover, the TGF-ß-positive cells that were astro-
cytes appeared to be HIV-1 negative. That HIV-1 infection
and TGF-ßl production did not exhibit a strong correlation
at the cellular level suggested that HIV-1-infected cells may
release a factor(s) that induces TGF-0 production and/or
that other stimuli induce production of TGF-ß by the un-
infected cells .
HIV-1-Infected Monocytes Produce 7GRß .
￿
To determine
whether HIV-1 infection of monocyte-macrophages could
directly influence TGF-ß1 production by these cells, purified
peripheral blood monocytes (>95% CD14+) were exposed
to HIV1H a-L for 1 h, washed, and the cells monitored for
secretion ofTGF-ßl . As shown in Fig. 3, monocyte-macro-
phages exposed to HIV-1 as compared to control cells secreted
increased levels of latent TGF-ßl . TGF-ß1 bioactivity was
detected in acid-activated supernatants within 2-3 d after HIV -1
inoculation and increased further through day 11 of infec-
tion before beginning to decline.
To further explore HIV-1 regulation of TGF-ßl, mono-
cytemRNA were isolated and probed for bothTGF-ß1 and
HIV-1. Although monocytes constitutively express the 2.5-kb
message for TGF-ß1 (39-41), TGF-ß1 mRNA expression was
increased two- to threefold within 2-6 h after exposure to
HIV1, but before the onset of viral replication (not shown) .
This increase in TGF-ß was reflected by increased levels of
secreted TGF-ß1 activity (Fig. 3) . By day 7 after inoculation
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ofthe monocytes withHIV1, viral transcripts (6.5, 4.3, and
2.0 kb) were detected in the HIV-1-exposed, but not the un-
exposed, control cells . The intensity of the viral transcripts
increased to day 14 and then decreased (Fig. 4A) . Coinciding
with the period of viral replication, these HIV-1-infected
monocytes also expressed increased levels of 'fGF-ß1-specific
mRNA (Fig. 4 A) .
To control for potential differences inRNA levels, the blots
were stripped, probed for the constitutively expressed con-
trolmRNA for He7, and the ratio ofTGF-ß toHO RNA
determined. As shown in Fig. 4 B, the levels ofTGF-0mRNA
Figure 4 .
￿
Expression ofHIV-1 transcripts and TGF-ßmRNA in mono-
cytes exposed toHIV1 . (A) Northernblot analysis ofmRNA from mono-
cytes infected with HIV-1 and equivalent numbers of control cells at the
indicated intervals . RT levels peaked at day 14 (N9 x 105 cpm) in the
HIV-1-inoculated monocyte cultures. ThemRNA were hybridized sequen-
tially with probes forHIV1, TGF-,B, and He7 . (B) Densitometric analysis
of the Northern blots to determine the ratio of TGF-0 mRNA to He7
mRNA for each individual sample.E
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Figure 5. Induction of astrocyte TGF-0 production. Rat astrocyte
monolayers were cultured in DMEM with FCS only or in supernatants
(diluted 1:10) from control or infected monorytes obtained 12 dafterin-
oculationwith HIV1. Astrocytes werealso cultured with 20 ng/mlTGF-0.
After4-hincubation with the supernatants or TGF-0, the astrocyte cul-
ture medium wasaspirated, thecells washed extensively, andfreshmedium
added. Aftera36-h incubation, thecell-free astrocyteculturesupernatants
were harvested and assayed for TGF-0 activity.
compared to He7 mRNA on the same blots were elevated
several-fold in the HIV-1-infected monorytes as compared to
the control cells. This augmented expression of TGF-(31
mRNA was most apparent at the beginning of viral replica-
tion. Thus, as shown for other monocyte products (20, 21,
42, 43), it appears that both the initial interaction of HIV-1
with monorytes and the onset ofproductiveinfection stimu-
late monorytes, likely by distinct signaling pathways, to
generate increased levels of TGF-01.
HIV-1-Infected Monocyte Products Stimulate Cultured Astro-
cytes to Produce TF-0. Since astrorytes do not appear to
be infected with HIV-1, we investigated whether HIV-1-in-
fected monocyte-macrophagesmight secrete a factor(s) capable
of upregulating TGF-# production by astrorytes. Superna-
tants from cultures ofHIV-1-infected monorytes were added
to rat astrocyte monolayers and the secreted astrocyte prod-
ucts monitored for TGF-0. Whereas untreated astrorytes in
DMEM and astrorytes treated with control monocyte super-
natants produced undetectable or minimal levels of TGF-(3,
astrorytes treated with HIV-1-infected monocyte supernatants
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secreted elevated levels of TGF-0 (Fig. 5). Moreover, since
HIV-1-infected monorytes secreted TGF-0, we also deter-
mined whether the addition of exogenous TGF-01 (10-20
ng/ml) to astrocyte cultures induced these cells to secrete
TGF-S.. As shown in Fig. 5, astrorytes that were pulsed with
TGF-0 subsequently secreted nanogram levels ofTGF-0 into
their culture media.
To confirm that it was astrocytes in the cultures that were
generating TGF-0, the monolayers were stained with anti-
bodies to GFAP (astrocyte-specific) and to TGF-91 by the
immunoperoxidase technique (Fig. 6). The majority of the
astrocyte monolayers were GFAP+ (>90%) and in parallel
cultures, similar numbers of cells were positive for TGF-01
peptide. Although a small percentage of the cells in the cul-
tures stained positively with mAb OX42, which identifies
tissue macrophages and microglia (Fig. 6 B), the localization
of TGF-0 peptide by immunoperoxidase and TGF-0 mRNA
by in situ hybridization in astrocytes (Fig. 6, C and D) clearly
documents that the astrocytes produce TGF-S. These data
implicate a link between the presence of HIV-1-infected
mononuclear phagocytes in the brain and the apparent acti-
vation of astrocytes to secrete TGF-S.
Discussion
In this studywe demonstrate that the peptide TGF-/31 is
present in the brain tissues of patients with AIDS, but not
in normalbrain tissue. This potent immunoregulatory cytokine
was primarily associated with two populations ofcells: cells
of the mononuclear phagocytic lineage and astrocytes. Al-
though one of the brain specimens was CMV positive and
one was infected with toxoplasma, the only pathogen common
to all four tissues appeared to be HIV-1, suggesting an as-
sociation between HIV-1 infection and the production of
TGF-/31. The combination of in situ hybridization for HIV-1
RNA and immunohistochemical staining for TGF-01 showed
that although the frequency of HIV-1-infected mononuclear
phagocytes within the brain is high (1, 2), monocytic cells
expressing TGF-01 were not universally HIV-1 positive. These
observations suggested that HIV-1-infected cells might be
influencing the production of TGF-fl1 by uninfected cells.
One population of HIV-1-negative cells foundto be TGF-fit
positive was identified as astrocytes. The number of astro-
cytespositive for TGF-0 was usually highest in areasassociated
with tissue abnormalities, whereas fewer or no TGF-(31-
positive astrocytes were identified in areas that appeared
normal. Although astrorytes cannot be infected by HIV-1
in culture (44), we infected monorytes with HIV-1 in vitro
to explore possiblemechanisms ofTGF-0 regulation in these
cells. Exposure of monorytes to HIV-1 induced this popula-
tion of cells to produce TGF-(3. Although the mechanism
of HIV-1-induced TGF-0 secretion has not been elucidated,
it appears similar to HIV-1 upregulation ofmonocyte-macro-
phage productionofothercytokines, including ILL TNF-a,
and 11,6 (20, 21, 42, 43). Interestingly, the early increase in
TGF-0 activity, before evidence of viral replication in the
monorytes, appears to mimic the ability of HIV-1 and/or the
envelope glycoprotein gp120 to interact with the CD4 mole-Figure 6 .
￿
Identification of cells producing TGF-ß in astrocyte cultures . Astrocyte cultures prepared as in Fig . 5 were stained by immunoperoxidase
with an antibody to GFAP (A), mAb OX42 (B), and an antibody to TGF-0 (D) . Parallel cultures (C) were probed for TGF-ß mRNA by in situ
hybridization as described in Materials and Methods (original magnification, x64) .
cule and initiate signal transduction leading to transient stim-
ulation of other monocyte functions including cytokine re-
lease (16, 17, 20, 21, 45) . However, increased TGF-ß may
occur by other virally dependent mechanisms . Thus, the im-
pact of the virus on monocyte cytokine production appears
to be biphasic : an initial response to ligand-CD4 receptor
signal transduction, and a subsequent upregulation during
viral replication, possibly mediated by products of the viral
genome.
Increased TGF-ß secretion by HIV-1-infected monocytes
in culture is consistent with the elevated levels of constitu-
tively expressed TGF-ß1 mRNA in mononuclear cells from
AIDS patients (reference 46, McCartney-Francis, unpublished
observations) and with the elevated circulating levels ofTGF-ß
recently demonstrated in AIDS patients (47) . These observa-
tions implicate monocyte-macrophage-derived TGF-ß not
only locally in the pathogenesis ofAIDS-related encephalop-
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athy, but also systemically in the development of immune
dysregulation (25, 27, 48) characteristic of AIDS .
Although an association between viral transformation of
cells and increased levels ofTGF-ßmRNA and polypeptide
secretion has been observed in previous studies using Harvey
or Maloney sarcoma-virus and feline sarcoma virus (49-51),
to our knowledge, no one has previously reported thatHIV-1
can induceTGF-ß secretion. Subsequent to the induction of
TGF-ß in infected cells, the release ofTGF-ß by these cells
likely promotes additional cytokine production in an auto-
crine and/or paracrine fashion (25, 39) . Consequently, both
resident and recruited monocytic populations localized in the
brains of theAIDS patients, some infected withHIV1, some
not, may produce TGF-ß . The paracrine actions of TGF-ß
may extend to other cell populations, including astrocytes,
thereby amplifying the impact of the virus on surrounding
neural cells, even if these neural cells do not support produc-tive viralinfection. Astrocytes also secrete cytokines~ including
TNF-a, which is neurotoxic and contributes to destruction
ofoligodendroglial cells and degeneration of the myelin sheath
(22, 23, 52, 53). It appears increasingly probable that astro-
cytes exert an active influence on the pathogenesis of HIV
CNS disease. Their ability to secrete TGF-0 is in keeping
with their other known capabilities, but adds a new dimen-
sion to theirrole in perpetuating the neuropathology associated
with AIDS. The strategic location of astrocytes may enable
local release of regulatory factors such as TGF-0 to initiate
recruitment of monocytes and microglia within the brain to
local sites of infection and/or injury. The frequent perivas-
cular distribution of HIV-1-infected macrophages is consis-
tent with a migration pattern of the circulating monocytes
from the vessels into the brain promoted by potent chemoat-
tractants such as TGF-/3.
Although TGF-01 is not normally foundin the adult human
brain, it is present in rodent brain during embryogenesis (38)
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to inflammation and tissue repair. Moreover, the ability of
HIV-1-infected mononuclear phagocyte products to stimu-
late aberrant astrocyte activities suggests a pivotal role for
the monocytec cells once they reach the CNS in the initia-
tion and perpetuation of the intracerebral pathology charac-
teristic of AIDS.
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